Ritodrine-induced erythematous papular eruption in 14 pregnant women.
Article Details
- CitationCopy to clipboard
Sato Y, Teraki Y, Izaki S, Baba K
Ritodrine-induced erythematous papular eruption in 14 pregnant women.
Int J Dermatol. 2010 Dec;49(12):1450-3. doi: 10.1111/j.1365-4632.2010.04633.x.
- PubMed ID
- 21091685 [ View in PubMed]
- Abstract
BACKGROUND: Ritodrine hydrochloride, a beta2-adrenergic agonist, has been used for the treatment of pre-term labor as a relatively safe agent, although tolerable side-effects have been occasionally reported. OBJECTIVE: The purpose of this study was to assess our clinical experience of skin eruptions caused by ritodrine. METHODS: Fourteen pregnant women with pruritic skin eruptions associated with the administration of ritodrine for pre-term labor were examined in Saitama Medical Center Hospital between 2005 and 2008. RESULTS: Patients included both primigravidas and multigravidas. Their mean age was 33.7 years (range: 27-41 years). Almost all subjects were in the third trimester of pregnancy. Skin eruptions occurred 7-27 days (mean: 14.9 days) after the start of intravenous or oral ritodrine. In eight patients, the eruption occurred after an increase in the dose of the drug. The reaction was characterized by a pruritic, erythematous, papular eruption, mainly distributed on the abdomen and upper extremities. Lymphocyte transformation tests for ritodrine were positive in five of the eight patients. CONCLUSIONS: Ritodrine-induced, erythematous, papular eruption probably occurs more frequently than has been previously estimated. An immunologic mechanism may play a role in the development of this eruption caused by ritodrine, although the reaction is somewhat dependent on the dose.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ritodrine Beta-2 adrenergic receptor Protein Humans YesAgonistDetails